This study is currently not recruiting participants.

Evaluation of Adalimumab Effectiveness in Anti-TNF Naive Pediatric Patients with Crohn's Disease in Clinical Practice

Investigating the Duration and Effectiveness of an Investigational Medication in Pediatric Crohn's Disease

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to examine the duration and effectiveness of adalimumab therapy in pediatric Crohn's disease within the ICN network.

Detailed description of study

The purpose of this study is to examine the duration and effectiveness of adalimumab therapy in pediatric Crohn's disease within the ICN network.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Crohn's disease
  • Age: 100 years or below
  • Gender: All

The purpose of this study is to examine the duration and effectiveness of an investigational medication in children with Crohn's disease. Crohn's disease is a condition that causes inflammation in the digestive tract, which can lead to symptoms like stomach pain and diarrhea.

Participants in this study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine. The study will monitor the effects of the treatment over time.

  • Who can participate: Children aged 6 to 17 diagnosed with Crohn's disease may be eligible to participate.
  • Study details: Participants will receive either the investigational medication or a placebo.
Updated on 19 Feb 2024. Study ID: 1601375502

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team